FDA Approves Stiolto Respimat Supplemental New Drug Application (sNDA) to Add Data on COPD Exacerbation Reduction

Media coverage

• Title	FDA Approves Stiolto Respimat Supplemental New Drug Application (sNDA) to Add Data on COPD Exacerbation Reduction
  Media name/outlet	Pharmacy Choice
  Country	United States
  Date	10/11/18
  Persons	Antonio R Anzueto